• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

novabay

NovaBay Pharmaceuticals closes acquisition of Dermadoctor

November 8, 2021 By Sean Whooley

NovaBay Pharmaceuticals

NovaBay Pharmaceuticals (NYSE:NBY) announced today that it closed its previously announced acquisition of skincare treatment developer Dermadoctor. Emeryville, California-based NovaBay develops the Avenova antimicrobial lid and lash spray, the CelleRx clinical reset and the NeutroPhase skin and wound cleanser for wound healing, all formulated with its patented, pure, stable, pharmaceutical-grade hypochlorous acid. In September, the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Materials Testing, Optical/Ophthalmic, Pharmaceuticals, Wound Care Tagged With: Dermadoctor, novabay

NovaBay prices $15M private placement

November 1, 2021 By Sean Whooley

NovaBay Pharmaceuticals

NovaBay Pharmaceuticals (NYSE:NBY) announced today that it entered into a securities purchase agreement, with proceeds of approximately $15 million. Emeryville, California-based NovaBay’s agreement with certain institutional investors occurred in connection with a private placement of 15,000 shares of a newly created Series B non-voting convertible preferred stock. The Series B preferred stock comes in at […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Optical/Ophthalmic, Pharmaceuticals, Wound Care Tagged With: Dermadoctor, novabay

NovaBay Pharmaceuticals to distribute Okra Limited’s dry eye products

August 19, 2021 By Sean Whooley

NovaBay Pharmaceuticals

NovaBay Pharmaceuticals (NYSE:NBY) announced today that it agreed with Okra Limited to distribute its Zocular dry eye products. The agreement allows NovaBay to distribute Zocular dry eye products alongside Avenova in its physician-dispensed sales channel. Zocular products are formulated with patented Zokrex technology, which contains activated natural okra polysaccharide complexes designed to gently and effectively […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic Tagged With: novabay

NovaBay raises $2.4m

July 5, 2019 By Sarah Faulkner

NovaBay Pharmaceuticals (NYSE:NBY) said this week that it raised $2.4 million in an offering that included three investors. The Emeryville, Calif.-based company has developed products for the eye care market, including a prescription for managing hygiene of the eyelids and lashes. NovaBay’s Avenova is formulated with a pure form of hypochlorous acid and is designed to […]

Filed Under: Featured, Funding Roundup, Optical/Ophthalmic Tagged With: novabay

NovaBay raises $6m in private placement

February 12, 2018 By Sarah Faulkner

NovaBay Pharmaceuticals (NYSE:NBY) has raised nearly $6 million after selling 1.7 million shares of common stock to OP Financial Investments Ltd., an institutional investor listed on the Hong Kong stock exchange. The Emeryville, Calif.-based company is developing non-antibiotic products for the topical anti-infective market. Its Avenova product is designed for the removal of microorganisms and debris on […]

Filed Under: Featured, Funding Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: novabay

NovaBay shareholders clear $10m stock deal

December 22, 2017 By Sarah Faulkner

NovaBay Pharmaceuticals (NYSE:NBY) said today that its shareholders have approved a deal to issue 2.4 million shares of common stock as part of a $10.3 million deal with Beijing-based Ch-gemstone Capital. The private placement is slated to close in January next year, contingent upon approval by regulatory authorities in China. “We appreciate our stockholders’ support […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: novabay

Tandem’s finance chief to retire at year’s end | Personnel Moves – Dec. 8, 2017

December 8, 2017 By Sarah Faulkner

Tandem Diabetes

Tandem Diabetes Care (NSDQ:TNDM) announced today that its EVP and chief financial exec, John Cajigas, will retire at the end of 2017. The company’s SVP of finance, Leigh Vosseller, is slated to take his place effective Jan. 1. Tandem noted that Cajigas’ retirement is not due to any disagreement or problem with the company’s accounting or […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, avitamedical, Bellerophon Therapeutics, biofilm, Biogen Idec, fractyllaboratories, novabay, Pediapharm, Tandem Diabetes Care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS